December 29, 2023
A Journey Through Immunization History
Because we’ve seen a lot of antivax narratives, let’s just give you a brief history of immunization. A Journey Through…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: vaccines
February 21, 2022
Valneva awarded up to £20 M by Scottish Enterprise to advance vaccine development
Valneva’s subsidiary Valneva Scotland has been awarded research and development funding of up to £20 million by Scottish Enterprise. The…
March 26, 2021
AstraZeneca pushes back vaccines-in-Italy topic
AstraZeneca has issued a statement to clarify a number of inaccurate statements relating to COVID-19 Vaccine AstraZeneca doses at the Anagni plant in Italy.
March 26, 2021
AZ’s trial of AZD1222 in the US confirms vaccine efficacy
AstraZeneca’s AZD1222 got positive high-level results from the primary analysis of the Phase III trial which in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021.
March 25, 2021
AstraZeneca answers accusation to stockpiling vaccines; 13M doses for COVAX, 16M for Europe
AstraZeneca has denied accusations of stockpiling vaccines stating that the process of manufacturing vaccines is very complex and time consuming…
March 23, 2021
Investigational AstraZeneca vaccine prevents COVID-19
Results from a large clinical trial in the United States and South America indicate that AstraZeneca’s COVID-19 vaccine, AZD1222, is…
April 14, 2020
Sanofi, GSK team up to make vaccine for COVID-19
Sanofi and GSK today announced teaming up to work on a vaccine for COVID-19, as Sanofi will contribute its S-protein COVID-19 antigen, and GSK contributing pandemic adjuvant technology.
March 24, 2020
Why you should continue to vaccinate your kids?
You want to do what is excellent for your kids. You know about the importance of baby gates, car seats, and other ways to keep them secure. But, did you know that the most excellent way to protect your kids is to make sure they have all of their vaccinations?
March 18, 2020
Vaxxas nets $5 million [AU$7.5 million] for clinical study of measles and rubella vaccination
Vaxxas got funding of US$5 million [AU$7.5 million] grant to speed up its clinical pipeline of innovative vaccines.
September 3, 2019
Janssen nets FDA’s Breakthrough Therapy Designation for investigational prophylactic vaccine for the prevention of respiratory syncytial virus in older adults
The Janssen Pharmaceutical Companies of Johnson & Johnson got the FDA’s Breakthrough Therapy Designation for its investigational prophylactic vaccine for the prevention of #respiratory syncytial virus (RSV)- mediated lower respiratory tract disease in adults aged 60 years or older. @JNJNews